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After much activity on a large number of common human diseases it has now been demonstrated 
beyond doubt that polymorphism in the human genome is a major contributor to disease 
susceptibility, with the genome-wide association scan methodology proving to be particularly 
adept at identifying loci harboring common DNA polymorphisms of moderate to high impact on 
disease risk [1]. As cohort sample sizes increase more loci of ever-weaker effects will be 
discovered, with the expectation being that specific pathways fundamental to particular diseases 
will be uncovered [2]. These will then offer scope for clinical intervention. 
 There are still many obstacles to overcome, logistical, technical, and theoretical. 
Logistical obstacles include the collection of ever-larger cohorts with the concurrent need to 
gather together very detailed medical and environmental measures and to share these resources 
across different ethical jurisdictions in large collaborative projects. Technical obstacles include 
the need to develop efficient methods for genotyping complex DNA polymorphisms, such as 
structural variations [3], and to establish high-throughput strategies for discovering rare variants 
that may be of greater singular impact on disease susceptibility than common polymorphisms 
[4,5]. Theoretical obstacles include the fact that, for most common diseases, a much smaller 
proportion than expected of the heritability of the disease is being accounted for by the DNA 
polymorphisms so far scanned. This has led to some skepticism regarding the overall usefulness 
of the genome-wide approach but has also made those actively involved in the field aware that 
much is still left to discover and to comprehend [6].  
 So what is the current status of osteoarthritis genetics? A few years ago the genetic 
analysis of this disease began to emerge from the candidate-gene driven approach, with its 
inherent bias towards the known, and entered the agnostic approach of genome-wide association 
scans. Unfortunately, the powerful osteoarthritis scans have not yet published their findings, 
leaving us currently with the outcomes of the candidate studies as our basis for hypothesizing 
about the translational potential of genetic discoveries. Although these candidate studies have 
typically suffered from the quite usual dual shortfalls of testing only a proportion of the variation 
within the targeted locus in small, underpowered cohorts, several robust hits have nevertheless 
emerged [7]. The two most compelling are to common polymorphisms within the genes GDF5 
and DIO2. GDF5, also known as cartilage derived morphogenetic protein 1 (CDMP1), is a 
member of the transforming growth factor β (TGF-β) superfamily and participates in the 
development, maintenance and repair of bone, cartilage and other tissues of the synovial joint. A 
single nucleotide polymorphism (SNP), rs143383 (T/C), located within the 5' untranslated region 
of GDF5 is associated with osteoarthritis in Asian and European populations [8,9]. The 
associated T-allele demonstrates reduced expression of GDF5 both in vitro and in tissues 
extracted from the joints of osteoarthritis patients [10,11]. There is also evidence of other 
functional polymorphism within this gene, and of a trans-acting factor, DEAF-1, that 
differentially interacts with the two rs143383 alleles [12]. DIO2 codes for iodothyronine-
deiodinase enzyme type 2 (D2), a selenoprotein that converts intracellular inactive thyroid 
hormone to its active form. D2 is a provider of local bioactive thyroid hormone to target tissues, 
such as the growth plate. A common DIO2 haplotype, containing the minor allele of rs225014 
and the common allele of rs12885300, was, like GDF5 SNP rs143383, associated in Asian and 
European cohorts [13]. The GDF5 and DIO2 proteins are active during normal skeletal 
morphogenesis as well as in mature, adult tissues. The associations to polymorphism in GDF5 
and DIO2 therefore emphasize that we need to consider the role of early developmental events in 
the osteoarthritis disease process [14,15].  
 So what is the likelihood that genetic discoveries in osteoarthritis will have an impact in 
the clinic? Clearly, speculation is the current order of the day due to our still porous knowledge 
of the genetic architecture of this common arthritis, although hopefully this situation will be 
attenuated by the imminent genome scans. The first clinical benefit may be an enhancement of 
our ability to more accurately phenotype the disease, based less on overt clinical observation but 
more on the underlying genetic architecture, such that we may start classifying patients by the 
major pathways involved in their disease process. This may lead to more refined patients cohorts 
being selected for the downstream trialing of new treatments. The second benefit may be an 
enhanced capacity to predict the trajectory of disease progression, based around how genetically 
loaded a particular individual is. This approach considers the number of susceptibility loci 
inherited and their cumulative risk [16]. Such predictions sound relatively straightforward but 
clearly are not, being heavily dependent on the interaction of susceptibility loci with several other 
factors including other loci (epistasis), with somatic events such as epigenetic changes, and with 
the environment. Large-scale prospective cohort studies, with the concurrent analysis of 
appropriate tissues for epigenetic evaluations, will be required if we are ever to get a robust 
handle on how the genome, the epigenome and the environment interact in osteoarthritis 
initiation and progression [17]. The ultimate clinical benefit will be the development of new 
treatments. This is not too fanciful, in that if pathways amenable to intervention by small 
molecules are uncovered, then these can be explored with vigor. Alternatively, genetic 
discoveries may help guide developments in endogenous and exogenous cell-based treatments. 
One very important consideration in all the proposed clinical utilities of the genetic data, 
and one touched on earlier, is the actual point in an individuals development when the genetic 
deficit first manifests itself. If this is early, can we realistically expect individuals to embark on 
potentially prolonged treatments from relatively young ages? For example, it has been reported 
that the osteoarthritis-associated T-allele of the GDF5 SNP rs143383 is also associated with 
shorter stature, which is a developmental phenotype [18,19]. The salient question therefore is 
does this allele initially contribute to osteoarthritis risk during skeletogenesis and hence long 
before anyone would present at the clinic with even mild symptoms of the disease? Clearly, many 
proteins are pleiotropic and it may be that even if this were the case, adult-based interventions 
could at least attenuate any effect that susceptibility loci are having on disease progression and 
severity.  
 In conclusion, from an applied research perspective osteoarthritis is no different to other 
common diseases in that by understanding more of the fundamental origins of the disease it is 
anticipated that new avenues for clinical intervention will open up. Such interventions may not 
prevent disease initiation, if the initiating factors are laid down early in development, but may 
slow-down or halt progression. There are still a number of extremely difficult challenges ahead 
but these may seem less daunting once the data from the genome scans are in. There are also new 
tools on the horizon, such as whole genome sequencing, which will overcome some of the 
technical issues surrounding genetic research in common diseases. There is therefore a long way 
to go before osteoarthritis genetics translates to the clinic, but appropriate steps are being taken.  
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